Core Viewpoint - Baotai (688177.SH) reported a revenue of 934 million yuan for the fiscal year 2025, marking a year-on-year increase of 25.64%, while the net profit attributable to the parent company was a loss of 336 million yuan, an improvement from a loss of 510 million yuan in the previous year [1] Group 1: Financial Performance - The company achieved an operating revenue of 934 million yuan in 2025, reflecting a growth of 25.64% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 336 million yuan, which is an improvement from a loss of 510 million yuan in the same period last year [1] Group 2: Revenue Drivers - The increase in revenue is attributed to the company's active market expansion, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) steadily increasing compared to the previous year [1] - The company launched Ustekinumab injection (STARJEMZA®) in the United States during the reporting period, contributing to growth in both licensing income and sales revenue [1]

Core Viewpoint - The company Baiotai (688177.SH) is expected to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a decrease in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is projected to be between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The company is actively expanding its market presence, with steady sales growth for its products, including Adalimumab Injection (Geleli®) and Tocilizumab Injection (Shiruili®) compared to the previous year [1] - The launch of Ustinumab Injection (STARJEMZA®) in the United States has contributed to increased licensing and sales revenue [1]

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]